MedTrace Logo

Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults

NCT07304518 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 456

Last updated 2026-01-29

No results posted yet for this study

Summary

The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.

Conditions

Interventions

DRUG

PRT-064040 nasal spray

A single dose of PRT-064040 nasal spray

DRUG

Placebo

A single dose of placebo matched to PRT-064040 nasal spray

Sponsors & Collaborators

  • Sichuan Purity Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-26
Primary Completion
2026-09-30
Completion
2026-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07304518 on ClinicalTrials.gov